Literature DB >> 12445249

P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer.

R A M Sagarra1, L A L A Andrade, E Z Martinez, G A Pinto, K J Syrjänen, S F M Derchain.   

Abstract

The study was designed to evaluate the prognostic importance of clinical and pathologic variables with p53 and Bcl-2 in epithelial ovarian cancer using multivariate analysis. Tumor tissues from 90 patients were analyzed immunohistochemically for p53 and Bcl-2 expression. Hazard ratios were calculated in univariate and multivariate survival analyses. Forty-two (47%) were considered positive for p53 expression and 18 (20%) were positive for Bcl-2. Positive expression for p53 was less frequent in patients in FIGO stage I (22%). Positive staining for Bcl-2 correlated significantly with the histologic type (P < 0.01). No direct correlations could be demonstrated between p53 and Bcl-2 expression and age or histologic grade. In univariate analysis, p53 and Bcl-2 expression were not significantly correlated with overall survival, disease-free survival, or progression time. FIGO stage III and IV and residual disease > or =2 cm3 after first surgery were significantly correlated with poor outcome in univariate analysis. FIGO stage retained their independent prognostic value in multivariate analysis. Neither p53 nor Bcl-2 had any significant influence on outcome in multivariate survival analysis. FIGO stage proved to be the only significant independent prognostic factor in epithelial ovarian cancer, although residual disease remains correlated with disease-free survival.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12445249     DOI: 10.1046/j.1525-1438.2002.01135.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  12 in total

1.  The value of serum bcl-2 levels in advanced epithelial ovarian cancer.

Authors:  Faruk Tas; Derya Duranyildiz; Hilal Oguz; Hakan Camlica; Vildan Yasasever; Erkan Topuz
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 2.  Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies.

Authors:  Linjuan Xu; Jing Cai; Qiang Yang; Hui Ding; Liying Wu; Tao Li; Zehua Wang
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-18       Impact factor: 4.553

3.  Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma.

Authors:  Sohei Yamamoto; Hitoshi Tsuda; Tsunekazu Kita; Kazunari Maekawa; Kazuyuki Fujii; Kazuya Kudoh; Kenichi Furuya; Seiichi Tamai; Johji Inazawa; Osamu Matsubara
Journal:  Virchows Arch       Date:  2007-06-27       Impact factor: 4.064

Review 4.  Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.

Authors:  Sabita N Saldanha; Trygve O Tollefsbol
Journal:  J Cell Physiol       Date:  2014-04       Impact factor: 6.384

5.  Urinary levels of Bcl-2 are elevated in ovarian cancer patients.

Authors:  Nicole S Anderson; Yira Bermudez; Donna Badgwell; Ren Chen; Santo V Nicosia; Robert C Bast; Patricia A Kruk
Journal:  Gynecol Oncol       Date:  2008-11-12       Impact factor: 5.482

6.  Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.

Authors:  Hatice Ozer; Goncaimir Yenicesu; Sema Arici; Meral Cetin; Ersin Tuncer; Ali Cetin
Journal:  Diagn Pathol       Date:  2012-09-20       Impact factor: 2.644

7.  Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy.

Authors:  Binny Khandakar; Sandeep R Mathur; Lalit Kumar; Sunesh Kumar; Siddhartha Datta Gupta; Venkateswaran K Iyer; M Kalaivani
Journal:  Biomed Res Int       Date:  2014-04-17       Impact factor: 3.411

8.  Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.

Authors:  P de Graeff; A P G Crijns; S de Jong; M Boezen; W J Post; E G E de Vries; A G J van der Zee; G H de Bock
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

Review 9.  The consequence of oncomorphic TP53 mutations in ovarian cancer.

Authors:  Pavla Brachova; Kristina W Thiel; Kimberly K Leslie
Journal:  Int J Mol Sci       Date:  2013-09-23       Impact factor: 5.923

10.  Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.

Authors:  Cécile Le Page; David G Huntsman; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  Cancers (Basel)       Date:  2010-05-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.